The Chinese team looks forward to their next match after..
The antiviral drug called Molnupiravir may soon be commercially available in the country as Merck & Co Inc. (MSD) applied for its emergency use in the country.
Pharmaceutical firm Merck & Co. Inc (MSD) has applied for emergency use authorization (EUA) of its innovative wonder antiviral drug, Molnupiravir, in the Philippines.
On Thursday, Food and Drug Administration (FDA) Director-General Eric Domingo informed that the American drugmaker applied its EUA last week, and is currently being evaluated.
Domingo added that the experts have questions for the applicant that needed to be answered.
The director-general pointed out that the COVID-19 antiviral pill has not yet been made commercially available in the country, but several hospitals that have ‘compassionate special permit’ can use it for their patients. Earlier, FDA has approved 31 Philippine hospitals the “compassionate use.”
According to Merck, it was eyeing to produce 10 million courses of the antiviral pill by the end of 2021, and at least 20 million is set to be manufactured the following year.
Earlier in October, the FDA has approved the EUA of a COVID-19 treatment drug called Ronapreve or REGEN-COV, manufactured by Swiss multinational healthcare company Roche. It was the first drug to get a local grant.
Related story: In world’s first, UK approves use of anti-COVID pill